# Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

> **NCT06526104** · PHASE2 · RECRUITING · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 32 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Cirrhosis, Liver

## Interventions

- **DRUG:** Tremelimumab
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT06526104
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-02
- **Primary completion:** 2027-10-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06526104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06526104, "Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06526104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*